A Study Of The Selective PKC-β Inhibitor MS- 553
Public ClinicalTrials.gov record NCT03492125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study identification
- NCT ID
- NCT03492125
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MingSight Pharmaceuticals, Inc
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Interventions
- MS-553 Drug
- Rituximab Drug
- acalabrutinib Drug
- obinutuzumab Drug
- venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 24, 2018
- Primary completion
- Nov 27, 2023
- Completion
- Nov 27, 2023
- Last update posted
- Apr 9, 2025
2018 – 2023
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Columbia University, Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| The Ohio State University, James Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| MD Anderson Cancer Center, Department of Leukemia | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03492125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03492125 live on ClinicalTrials.gov.